Four months ago, Neocortix announced the launch of the Rosetta @ Home port , allowing Arm devices to participate in a protein folding study aimed at finding a vaccine for COVID-19. At that time, the company announced that work was underway to port to Arm Folding @ Home, another distributed computing project aimed at achieving the same goal.
Now Neocortix has reported success on both fronts. “We've ported Folding @ Home and Rosetta @ Home for Arm-based devices to enable billions of high-performance mobile devices to work towards finding a vaccine for COVID-19,” explains Lloyd Watts, Founder and CEO of Neocortix. “We saw an opportunity to use our Neocortix Cloud Services platform to help the most sought after scientific projects in their need for computing resources, and did it on a large scale. "
“We are moving into a future with a trillion connected devices, and the innovation is that this approach addresses one of the toughest challenges of linking multiple devices from around the world into a single cloud,” adds Paul Williamson, vice president and chief communications officer with Arm's business customers, "Arm's partnership with Neocortix means Arm technology can now contribute to mission-critical COVID-19 research, and it's amazing to see Arm's global developer ecosystem coming together to support this effort together."
“We've seen growing computing power in phones and other mobile devices in recent years,” agrees Greg Bowman, Project Director at Folding @ Home. “This collaboration between Neocortix and Arm has provided us with an ideal opportunity to leverage mobile resources to accelerate our research on COVID-19. ".
Folding @ Home and Rosetta @ Home are already running on the Neocortix Scalable Compute distributed computing platform and are feeding the results back to scientific projects. Additional technical details can be found in the Neocortix Coronablog .